Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital

Constitution d'Une Collection Biologique à Des Fins de Recherche médicale Pour Les Patients du Centre de référence Des Maladies Rares Des Vaisseaux du Cerveau et de l'Oeil à l'hôpital Lariboisière

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07264972

Acronym

B-MRVC

Enrollment

500

Registered

2025-12-04

Start date

2021-01-21

Completion date

2027-07-31

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Disease

Keywords

rare cerebrovascular disease

Brief summary

The aim of establishing a biological collection associated with the existing rare cerebral vascular disease cohort is to identify new prognostic or disease progression biomarkers that could improve patient care or identify new therapeutic targets.

Interventions

OTHERadditional samples for research purposes

Blood and urine sampling

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed diagnosis of a rare cerebral vascular disease of the brain, including: Familial intracranial aneurysms, cerebral amyloid angiopathy, CADASIL, familial cerebral cavernoma, familial cervical or intracranial artery dissection, vascular leukoencephalopathy (hereditary), familial hemiplegic migraine, cerebral arteriovenous malformation, moya-moya, cerebral venous thrombosis, hereditary retinal tortuosity, cerebro-retinal vasculopathies, other known rare diseases, or other rare diseases that are undetermined or not yet described. * Participation in the MVCR cohort * Adults \>18 years old * Affiliation with French social security or beneficiary - Signature of informed consent

Exclusion criteria

* Incompatibility with long-term follow-up at CERVCO * Patient under guardianship/conservatorship * Pregnant or breastfeeding women * Patient under AME

Design outcomes

Primary

Measure	Time frame	Description
Time required for sample storage (freezing) to ensure the stability of most measurable elements in a biological sample	Up to 2 years after inclusion	for each sample

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026